New Task Order Award for AS03B H7N9 Vaccine Clinical Study
Award Notice Posted
- Solicitation number
- RTOR_Number_2018-0014
- Agency
-
Immediate Office of the Secretary
Department of Health and Human Services
- Awarded
- to Glaxosmithkline, LLC
- Set-aside
- No set-aside
Opportunity facts
- Contract number
- HHSO100201600004I-75A50119F33009 Federal contract award
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- PSC
- Not on record
Notice details come from SAM.gov. Updated .
Notice text
This new task order award is to conduct a clinical study to assess the dose-sparing ability of full or half doses of AS03 adjuvant system in combination with GlaxoSmithKline LLC-manufactured influenza A/Hong Kong/125/2017-like (H7N9) virus vaccine present in the National Pre-Pandemic Influenza Vaccine Stockpile to generate an immune response after two (2) doses in healthy adults and older adults. The results of that Clinical Study will provide information supporting a considerable antigen and adjuvant dose sparing, crucial for mass vaccination during a pandemic event. This Task Order's term is expected to complete by July 1, 2022. Please see the posted Justification for an Exception to Fair Opportunity (JEFO) for additional information.. Awarded Vendors: GLAXOSMITHKLINE LLC. Contract Award Dollar Amount: $17,546,668.00. Contract Award Date: 2019-08-28.
Files
| File | Type | Posted |
|---|---|---|
| JEFO_for_GSK_AS03B_H7N9_Clinical_Study_Task_Order.pdf |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity